Is this your business? Claim it to manage your IP and profile
The xT CDx is a sophisticated tumor profiling solution designed to advance precision oncology care for solid malignancies. This assay uses next-generation sequencing to assess alterations in 648 genes, identifying single nucleotide variants, multi-nucleotide variants, and insertions/deletions. It also evaluates microsatellite instability status and serves as a companion diagnostic to explore potential treatment avenues according to specific therapeutic product labeling. Uniquely, xT CDx offers mutation profiling through samplings from both formalin-fixed paraffin-embedded tumor tissues and matched normal samples such as blood or saliva, enhancing diagnostic clarity and treatment direction for patients with solid tumors. The comprehensive report generated includes valuable insights that can inform the personalized treatment path for cancer patients.
The xF+ Liquid Biopsy Panel is a non-invasive testing solution that utilizes ctDNA sequencing to evaluate up to 523 genes specifically tailored for identifying actionable variants in solid tumors. Developed for comprehensive genetic profiling, this panel excels in detecting circulating tumor DNA elements in blood samples, offering a vital complement to tissue-based genotyping in certain cancer types. It includes enhanced regions for deeper sequencing accuracy and delivers results on genomic mutations such as SNVs, insertions/deletions, and CNVs, along with oncological markers like MSI-H and bTMB. This depth of analysis provides clinicians with critical information about a tumor's genetic landscape, which aids in personalizing treatment strategies and monitoring disease progression non-invasively.
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
